Skip to main content

Advertisement

SpringerLink
Log in

Emerging therapeutic options for atopic dermatitis: Beyond TIMs

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts both patients and their families. Although current therapies provide relief of symptoms for most but not all patients, they do not prevent or eradicate the disease. In this new era of biological therapy, medications that precisely target the molecular mediators of inflammation are being developed at a rapid pace. These biologic agents have proven useful for treating many inflammatory illnesses, as well as providing insight into disease pathogenesis. In atopic dermatitis, these new therapies may prove highly useful to both treat and prevent the disease. In this review article, we briefly review the pathogenesis of AD to discuss current therapies and to introduce potential new treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Williams HC: Clinical practice. atopic dermatitis. N Engl J Med 2005, 352:2314–2324. Excellent, case-based clinical review.

    Article  PubMed  CAS  Google Scholar 

  2. Schultz-Larsen F, Hanifin JM: Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002, 22:1–24.

    Article  Google Scholar 

  3. Taylor B, Wadsworth J, Wadsworth M, et al.: Changes in the reported prevalence of childhood eczema since the 1939–1945 war. Lancet 1984, 2:1255–1257

    Article  PubMed  CAS  Google Scholar 

  4. Verboom P, Hakkaart-Van L, Sturkenboom M, et al.: The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147:716–724.

    Article  PubMed  CAS  Google Scholar 

  5. Kemp AS: Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics 2003, 21:105–113. A cost analysis of the economic burden of atopic dermatitis.

    Article  PubMed  Google Scholar 

  6. Paller AS, McAlister RO, Doyle JJ, et al.: Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment Clin Pediatr 2002, 41:323–332.

    Article  Google Scholar 

  7. Leung DYM, Boguniewicz M, Howell MD, et al.: New insights into atopic dermatitis. J Clin Invest 2004, 113:651–657. A thorough review of the current understanding of AD pathogenesis.

    Article  PubMed  CAS  Google Scholar 

  8. Mihm MC, Soter NA, Dvorak HF, et al.: The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976, 67:305–312.

    Article  PubMed  Google Scholar 

  9. Leung DY, Bieber T: Atopic dermatitis. Lancet 2003, 361:151–160. A review of the pathophysiology and current clinical therapy for atopic dermatitis.

    Article  PubMed  Google Scholar 

  10. Leung DY, Harbeck R, Bina P, et al.: Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993, 92:1374–1380.

    PubMed  CAS  Google Scholar 

  11. Nilsson EJ, Henning CG, Magnusson J: Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992, 27:29–34.

    PubMed  CAS  Google Scholar 

  12. Imokawa G: Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol 2001, 45:S29-S32.

    Article  PubMed  CAS  Google Scholar 

  13. Chamlin SL, Kao J, Frieden IJ, et al.: Ceramide-dominant barrier lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002, 47:198–208.

    Article  PubMed  Google Scholar 

  14. Lucky AW, Leach AD, Laskarzewski P, et al.: Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997, 14:321–324.

    PubMed  CAS  Google Scholar 

  15. Hoare C, Li Wan Po A, Williams H: Systematic review of treatments for atopic eczema. Health Technol Assess 2000, 4:1–191. A comprehensive meta-analysis of standard therapies used for AD.

    PubMed  CAS  Google Scholar 

  16. Gottlieb AB: Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005, 53:S3-S16. Review of current and emerging therapies for psoriasis and AD that details the evidence, mechanism of action, and side-effect profile for each drug.

    Article  PubMed  Google Scholar 

  17. Friedlander SF, Hebert AA, Allen DB: Safety of.uticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. For the Fluticasone Pediatrics Safety Study Group. J Am Acad Dermatol 2002, 46:387–393.

    Article  PubMed  CAS  Google Scholar 

  18. Bornhovd E, Burgdorf WH, Wollenberg A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001, 45:736–743.

    Article  PubMed  CAS  Google Scholar 

  19. Eichenfeld LF, Lucky AW, Boguniewicz M, et al.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002, 46:495–504.

    Article  Google Scholar 

  20. Paller A, Eichenfield LF, Leung DY, et al.: 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001, 44:S47-S57.

    Article  PubMed  CAS  Google Scholar 

  21. US Food and Drug Administration: Food and Drug Magazine. March-April, 2006. http://www.fda.gov/fdac/ departs/2006/206_upd.html#eczema

  22. Koo JYM, Fleischer AB, Abramovits W, et al.: Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005, 53:S195-S205.

    Article  PubMed  Google Scholar 

  23. Klein PA, Clark RA: An evidence-based review of the efficacy of antihistamines in relieving pruritis in atopic dermatitis. Arch Dermatol 1999, 135:1522–1525.

    Article  PubMed  CAS  Google Scholar 

  24. Sampson, HA: The evaluation and management of food allergy in atopic dermatitis. Clin Dermatol 2003, 21:183–192.

    Article  PubMed  Google Scholar 

  25. Spuls PI, Witkamp L, Bossuyt PM, et al.: A systematic review of.ve systemic treatments for severe psoriasis. Br J Dermatol 1997, 137:943–949.

    Article  PubMed  CAS  Google Scholar 

  26. Shaffrali FC, Colver GB, Messenger AG, et al.: Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 2003, 48:417–419.

    Article  PubMed  Google Scholar 

  27. Roenigk HH Jr, Auerbach R, Maibach H, et al.: Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 38:478–485.

    Article  PubMed  Google Scholar 

  28. Sowden JM, Berth-Jones J, Ross JS, et al.: Double-blind, controlled, crossover study of cyclosporine in adults with severe refractory atopic dermatitis. Lancet 1991, 338:137–140.

    Article  PubMed  CAS  Google Scholar 

  29. Wolff K, Fleming C, Hanifin J, et al.: Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005, 152:1296–1303.

    Article  PubMed  CAS  Google Scholar 

  30. Novartis and Fujisawa FDA Briefing Statements: Pediatric Advisory Committee Meeting of the US Food and Drug Administration. Washington, DC, 2005. http://www.fda. gov/ohrms/dockets/ac/05/Briefing/2005-4089b2.htm

  31. Aspeslet L, Freitag D, Trepanier D, et al.: ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc 2001, 33:1048–1051.

    Article  PubMed  CAS  Google Scholar 

  32. Grundmann-Kollmann M, Podda M, Ochsendorf F, et al.:Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001, 137:870–873.

    PubMed  CAS  Google Scholar 

  33. Benez A, Fierlbeck G: Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001, 144:638–639.

    Article  PubMed  CAS  Google Scholar 

  34. Jain J, Almquist SJ, Heiser AD, et al.: Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5’-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther 2002, 302:1272–1277.

    Article  PubMed  CAS  Google Scholar 

  35. Berth-Jones J, Takwale A, Tan E, et al.: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002, 147:324–330.

    Article  PubMed  CAS  Google Scholar 

  36. Kuanprasert N, Herbert O, Barneston RS: Clinical improvements in and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002, 43:125–127.

    Article  PubMed  Google Scholar 

  37. Hanifin JM, Schneider LC, Leung DY, et al.: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993,; 28:189–197.

    Article  PubMed  CAS  Google Scholar 

  38. Stevens SR, Hanifin JM, Hamilton T, et al.: Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998, 134:799–804.

    Article  PubMed  CAS  Google Scholar 

  39. Schneider LC, Baz Z, Zarcone C, et al.: Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 1998, 80:263–268.

    Article  PubMed  CAS  Google Scholar 

  40. Wuthrich B, Benz A, Skvaril F: IgE and IgG4 levels in children with atopic dermatitis. Dermatologica 1983, 166:229–235.

    Article  PubMed  CAS  Google Scholar 

  41. MacGlashan DW Jr, Bochner BS, Adelman DC, et al.:Downregulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438–1445.

    PubMed  CAS  Google Scholar 

  42. Babu KS, Arshad SH, Holgate ST: Anti-IgE treatment: an update. Allergy 2001, 56:1121–1128. Review of omalizumab and FcεRI receptor.

    Article  PubMed  CAS  Google Scholar 

  43. Beck LA, Marcotte GV, MacGlashan D, et al.: Omalizumab- induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004, 114:527–530.

    Article  PubMed  CAS  Google Scholar 

  44. Lane JE, Cheyney JM, Lane TN, et al.: Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006, 54:68–72.

    Article  PubMed  Google Scholar 

  45. Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005, 53:338–340.

    Article  PubMed  Google Scholar 

  46. Leonardi CL: Efalizumab: an overview. J Am Acad Dermatol 2003, 49:S98-S104.

    Article  PubMed  Google Scholar 

  47. Gordon KB, Papp KA, Hamilton TK, et al.: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290:3073–3080.

    Article  PubMed  CAS  Google Scholar 

  48. Leung DY, Pober JS, Cotran RS: Expression of endothelialleukocyte adhesion molecule-1 in elicited late phase allergic reaction set. J Clin Invest 1991, 87:1805–1809.

    Article  PubMed  CAS  Google Scholar 

  49. Howarth PH, Babu KS, Arshad HS, et al.: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependant asthma. Thorax 2005, 60:1012–1018.

    Article  PubMed  CAS  Google Scholar 

  50. Berry MA, Hargadon D, Shelley M, et al.: Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697–708.

    Article  PubMed  CAS  Google Scholar 

  51. Buka RL, Resh B, Roberts B, et al.: Etanercept is minimally effective in two children with atopic dermatitis. J Am Acad Dermatol 2005, 53:358–359.

    Article  PubMed  Google Scholar 

  52. Jacobi A, Antoni C, Manger B, et al.: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005, 52:522–526.

    Article  PubMed  Google Scholar 

  53. Kalliomaki M, Salminen S, Arvilommi H, et al.: Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001, 357:1076–1079.

    Article  PubMed  CAS  Google Scholar 

  54. Weston S, Halbert A, Richmond P, et al.: Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch Dis Child 2005, 90:892–897.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Johns Hopkins Allergy and Asthma Center, 5501 Hopkins Bayview Circle, Unit Office 3A.62, 21224, Baltimore, MD, USA

    Lisa A. Beck MD

Authors
  1. Edward R. Conner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa A. Beck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa A. Beck MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conner, E.R., Beck, L.A. Emerging therapeutic options for atopic dermatitis: Beyond TIMs. Curr Allergy Asthma Rep 6, 275–281 (2006). https://doi.org/10.1007/s11882-006-0060-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-006-0060-1

Keywords

Search

Navigation